Acute myeloid leukemia (AML) which include - acute promyelocytic, monocytic, myelomonocytic, megakaryoblastic, and erythroid leukemias; acute lymphocytic leukemia (ALL); meningeal leukemia and other meningeal neoplasms; chronic myelogenous leukemia (CML); non-Hodgkin's lymphomas in children; myelodysplastic syndrome. It is used principally as a component of various chemotherapeutic regimens.
100 mg/m2/day by continuous IV infusion from day 1 through 7 or 100 mg/ m2IV every 12 hours day 1 through 7 [in combination with other antineoplastics]. Consult specialist literature for further information.
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
It is a synthetic pyrimidine nucleoside in which the sugar moiety is arabinose instead of ribose or deoxyribose. It is a pyrimidine antagonist antimetabolite, which is activated to cytarabine triphosphate in the tissues. This in turn inhibits of DNA polymerase and incorporation of cytarabine into DNA and RNA.
Only physicians experienced in cancer chemotherapy should use it; increased incidence of infections; increased incidence of hemorrhagic complications; blood counts should be performed at least once a week.
Hypersensitivity to the drug
Bone marrow suppression [main adverse reaction] with leukopenia, thrombocytopenia and anemia; nausea; vomiting; diarrhea and abdominal pain; oral ulceration; hepatic dysfunction